<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Cardiovascular disease: risk assessment: prediction charts" /><meta name="IX" content="Cardiovascular disease: risk assessment: prediction charts" /><title>How to use the Cardiovascular Risk Prediction Charts for Primary Prevention: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP10418-how-to-use-the-cardiovascular-risk-prediction-charts-for-primary-prevention.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP10418-how-to-use-the-cardiovascular-risk-prediction-charts-for-primary-prevention.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP10418-how-to-use-the-cardiovascular-risk-prediction-charts-for-primary-prevention.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP10417-cardiovascular-risk-prediction-charts.htm">Appendix Cardiovascular Risk Prediction Charts</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP10417-cardiovascular-risk-prediction-charts.htm" title="Previous: Appendix Cardiovascular Risk Prediction Charts">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP10421-medical-emergencies-in-the-community.htm" title="Next: Appendix Medical emergencies in the community">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>British National Formulary (14)</h3></li><li><a href="PHP959-kalten.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Kalten®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 2 Cardiovascular system &gt; 2.4 Beta-adrenoceptor blocking drugs &gt; ATENOLOL &gt; With diuretic</p></div></li><li><a href="PHP963-beta-adalat.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Beta-Adalat®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 2 Cardiovascular system &gt; 2.4 Beta-adrenoceptor blocking drugs &gt; ATENOLOL &gt; With calcium-channel blocker</p></div></li><li><a href="PHP964-tenif.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tenif®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 2 Cardiovascular system &gt; 2.4 Beta-adrenoceptor blocking drugs &gt; ATENOLOL &gt; With calcium-channel blocker</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22cardiovascular+disease%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (14)</a></li></ul><ul><li><h3>Dietary Supplements (36)</h3></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c05.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Antioxidants</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; A</p></div></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c06.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Arginine</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; A</p></div></li><li><a href="http://www.medicinescomplete.com/mc/diet/2010/c15.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bromelain</a><div class="breadcrumb"><p><strong>Dietary Supplements</strong> &gt; Monographs &gt; B</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22cardiovascular+disease%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (36)</a></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/7200-a1-11-c.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Diabetes-associated cardiovascular disease</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antidiabetics &gt; Diabetes mellitus &gt; Diabetic complications</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/570-a2-2-d.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cardiovascular disease</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Nutritional Agents and Vitamins &gt; Dietary Modification</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy (5)</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/c56-sec1-006.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Inflammatory Disorders</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 1: The Science of Pharmacy &gt; Section 6: Pharmacokinetics and Pharmacodynamics &gt; 56 Principles of Immunology</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/c86-sec1-005.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Nutritional Management of Disease</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 2: The Practice of Pharmacy &gt; Section 8: The Scope of Pharmacy Practice &gt; 86 Nutrition in Pharmacy Practice</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/c105-sec1-0017.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cholesterol</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 2: The Practice of Pharmacy &gt; Section 10: Patient Care &gt; 105 Diagnostic Self-Care</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22cardiovascular+disease%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>How to use the Cardiovascular Risk Prediction Charts for Primary Prevention</h1><?highlighter on?><div id="pC" class="jN"><p>These charts are for estimating cardiovascular disease (CVD) risk (non-fatal myocardial infarction and stroke, coronary and stroke death and new angina pectoris) for individuals who have <strong>not</strong> already developed coronary heart disease (CHD) or other major atherosclerotic disease. They are an aid to making clinical decisions about how intensively to intervene on lifestyle and whether to use antihypertensive, lipid lowering and anti-platelet medication, but should <strong>not replace clinical judgment</strong>.</p><ul><li><p>The use of these charts is <strong>not appropriate</strong> for patients who have existing diseases which already put them at high risk such as:</p> </li></ul><ul class="cW"><li><p>- coronary heart disease or other major atherosclerotic disease;</p> </li><li><p>- familial hypercholesterolaemia or other inherited dyslipidaemias;</p> </li><li><p>- renal dysfunction including diabetic nephropathy;</p> </li><li><p>- type 1 and 2 diabetes mellitus.</p> </li></ul><ul><li><p>The charts should <strong>not</strong> be used to decide whether to introduce antihypertensive medication when blood pressure is persistently at or above 160/100 mmHg or when target organ damage due to hypertension is present. In both cases antihypertensive medication is recommended regardless of CVD risk. Similarly the charts should <strong>not</strong> be used to decide whether to introduce lipid-lowering medication when the ratio of serum total to HDL cholesterol exceeds 6. Such medication is generally then indicated regardless of estimated CVD risk.</p> </li><li><p>To estimate an individual's absolute 10-year risk of developing CVD choose the chart for his or her sex, lifetime smoking status and age. Within this square identify the level of risk according to the point where the coordinates for systolic blood pressure and the ratio of total cholesterol to high density lipoprotein (HDL) cholesterol meet. If no HDL cholesterol result is available, then assume this is 1.0 mmol/litre and the lipid scale can be used for total cholesterol alone.</p> </li><li><p>Higher risk individuals (red areas) are defined as those whose 10-year CVD risk exceeds 20%, which is approximately equivalent to the coronary heart disease risk of &gt; 15% over the same period.</p> </li><li><p>The chart also assists in identifying individuals whose 10-year CVD risk is moderately increased in the range 10–20% (orange areas) and those in whom risk is lower than 10% over 10 years (green areas).</p> </li><li><p>Smoking status should reflect lifetime exposure to tobacco and not simply tobacco use at the time of assessment. For example, those who have given up smoking within 5 years should be regarded as current smokers for the purposes of the charts.</p> </li><li><p>The initial blood pressure and the first random (non-fasting) total cholesterol and HDL cholesterol can be used to estimate an individual's risk. However, the decision on using drug therapy should generally be based on repeat risk factor measurements over a period of time.</p> </li><li><p>Men and women do not reach the level of risk predicted by the charts for the three age bands until they reach the ages 49, 59, and 69 years respectively. The charts will overestimate current risk most in the under 40s. Clinical judgement must be exercised in deciding on treatment in younger patients. However, it should be recognised that blood pressure and cholesterol tend to rise most and HDL cholesterol to decline most in younger people already with adverse levels. Left untreated, their risk at the age of 49 years is likely to be higher than the projected risk shown on the age-under-50-years chart. From age 70 years the CVD risk, especially for men, is usually ≥ 20% over 10 years and the charts will underestimate true total CVD risk.</p> </li><li><p>These charts (and all other currently available methods of CVD risk prediction) are based on groups of people with <strong>untreated</strong> levels of blood pressure, total cholesterol and HDL cholesterol. In patients already receiving antihypertensive therapy in whom the decision is to be made about whether to introduce lipid-lowering medication, or vice versa, the charts can only act as a guide. Unless recent pre-treatment risk factor values are available it is generally safest to assume that CVD risk is higher than that predicted by current levels of blood pressure or lipids on treatment.</p> </li><li><p>CVD risk is also higher than indicated in the charts for:</p> </li></ul><ul class="cW"><li><p>- those with a family history of premature CVD (male first-degree relatives aged &lt; 55 years and female first-degree relatives aged &lt; 65 years) which increases the risk by a factor of approximately 1.5;</p> </li><li><p>- men with HDL cholesterol &lt; 1 mmol/litre or women with HDL cholesterol &lt; 1.2 mmol/ litre;</p> </li><li><p>- those with raised triglyceride levels (&gt; 1.7 mmol/litre);</p> </li><li><p>- those with BMI ≥ 30 kg/m<sup>2</sup>;</p> </li><li><p>- women with premature menopause;</p> </li><li><p>- those who are not yet diabetic, but have impaired fasting glycaemia (6.1–6.9 mmol/ litre) or impaired glucose tolerance (2 hour glucose ≥ 7.8 mmol/litre but &lt; 11.1 mmol/ litre in an oral glucose tolerance test).</p> </li></ul><ul><li><p>The charts have not been validated in ethnic minorities and in some may underestimate CVD risk. For example, in people originating from the Indian subcontinent it is safest to assume that the CVD risk is higher than predicted from the charts (1.4 times).</p> </li><li><p>An individual can be shown on the chart the direction in which his or her risk of CVD can be reduced by changing smoking status, blood pressure, or cholesterol, but it should be borne in mind that the estimate of risk is for a group of people with similar risk factors and that within that group there will be considerable variation in risk. It should also be pointed out in younger people that the estimated risk will generally not be reached before the age of 50, if their current blood pressure and lipid levels remain unchanged. The charts are primarily to assist in directing intervention to those who typically stand to benefit most.</p> </li></ul><div class="cI"><p>The estimation of CVD risk in NICE clinical guideline 67 (May 2008): <em>Lipid modification–Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</em> (available at <a href="http://www.nice.org.uk">www.nice.org.uk</a>) differs from that shown here as follows:</p><ul><li><p>estimated CVD risk increases by a factor of 1.5 in those with a family history of premature CHD (male first-degree relatives aged &lt; 55 years and female first-degree relatives aged &lt; 65 years)</p> </li><li><p>estimated CVD risk increases by a factor of 1.5–2 if more than one first-degree relative has a history of premature CHD</p> </li><li><p>estimated CVD risk for South Asian <strong>men</strong> is increased by a factor of 1.4</p> </li><li><p>CVD risk is higher than estimated in those with BMI &gt; 40 kg/m<sup>2</sup></p> </li></ul><p>The NICE guideline does not include the recommendation to treat all patients with a serum total to HDL cholesterol ratio of greater than 6 with lipid-lowering drugs.</p><p>The NICE guideline advises that the following factor is also taken into account when calculating CVD risk:</p><ul><li><p>presence of left ventricular hypertrophy</p> </li></ul><p>In addition, NICE advises that all patients over the age of 75 years should be considered at increased risk of CVD, and are likely to benefit from treatment.</p><p>In February 2010, NICE withdrew the recommendation that the Framingham risk equation should be the equation of choice for assessment of CVD risk, but agreed that it should be considered as one of the possible equations to use.</p></div><p id="PHP10419"><img src="images/CV_risk_chart_p3.png" alt="Cardiovasculatr Risk Predication Chart 3" /></p><p id="PHP10420"><img src="images/CV_risk_chart_p4.png" alt="Cardiovasculatr Risk Predication Chart 4" /></p></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP10417-cardiovascular-risk-prediction-charts.htm">Previous: Appendix Cardiovascular Risk Prediction Charts</a> | <a class="top" href="PHP10418-how-to-use-the-cardiovascular-risk-prediction-charts-for-primary-prevention.htm#">Top</a> | <a accesskey="]" href="PHP10421-medical-emergencies-in-the-community.htm">Next: Appendix Medical emergencies in the community</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>